AngioDynamics ANGO
$11.73 −$0.08 (-0.68%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $11.73 0.00%
Open$11.62
Prev close$11.81
Day range$11.52 – $11.81
Volume363.7K
Market cap$493.30M
P/E (TTM)–
Dividend yield–
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Institutional ownership92.0%-1.15 pts vs. prior quarter
Institutions holding198-2 vs. prior quarter
Insider trades (recent)32 buys / 18 sellsNet buying
Short interest4.56% of floatDays to cover 1.5 · as of 15 Oct 2026
Short-sale volume share26.9%5-day average of daily volume
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$804.2K (12 inflow days, 8 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 33.6% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 2.96% to 4.56% of float over the last 6 biweekly reports (31 Jul 2026 to 15 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Y-Intercept (Hong Kong) Limited | Mutual Fund | 2026/Q3 | +78,328 | 0.3% |
| Stephen Trowbridge | Individual/Insider | 2026/Q3 | +41,823 | 0.4% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +69,108 | 1.1% |
| James Clemmer | Individual/Insider | 2026/Q3 | +90,208 | 1.5% |
| Laura Piccinini | Individual/Insider | 2026/Q3 | +67,286 | 0.2% |
| Chad Campbell | Individual/Insider | 2026/Q3 | +63,873 | 0.2% |
| Stephen Trowbridge | Individual/Insider | 2026/Q3 | +36,561 | 0.4% |
| Royce & Associates, LP | Mutual Fund | 2026/Q3 | +440,884 | 4.7% |
| Western Standard, LLC | Hedge Fund | 2026/Q3 | +387,188 | 0.9% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +335,145 | 1.4% |
| Armistice Capital LLC | Hedge Fund | 2026/Q3 | +329,000 | 5.2% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +193,751 | 0.5% |
| Systematic Financial Management LP | Mutual Fund | 2026/Q3 | +186,513 | 6.3% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +138,448 | 1.9% |
| BlackRock | Mutual Fund | 2026/Q3 | +117,328 | 9.0% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 29 Jul 2026 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Open Market Disposition | -23,370 | $14.72 | 64,745 |
| 21 Jul 2026 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Derivative Exercise and Sale | -1,671 | $13.82 | 88,115 |
| 21 Jul 2026 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Derivative Exercise and Retained | +4,023 | – | 88,115 |
| 21 Jul 2026 | James Clemmer | Chief Executive Officer | Derivative Exercise and Sale | -26,728 | $13.82 | 629,899 |
| 21 Jul 2026 | James Clemmer | Chief Executive Officer | Derivative Exercise and Retained | +25,630 | – | 629,899 |
| 21 Jul 2026 | Stephen Trowbridge | Chief Financial Officer | Derivative Exercise and Sale | -8,319 | $13.82 | 160,642 |
| 21 Jul 2026 | Stephen Trowbridge | Chief Financial Officer | Derivative Exercise and Retained | +7,977 | – | 160,642 |
| 21 Jul 2026 | Laura Piccinini | Senior VP and GM of Cardiovascular & International | Derivative Exercise and Sale | -4,506 | $13.82 | 81,929 |
| 21 Jul 2026 | Laura Piccinini | Senior VP and GM of Cardiovascular & International | Derivative Exercise and Retained | +3,541 | – | 81,929 |
| 21 Jul 2026 | Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | Derivative Exercise and Sale | -2,330 | $13.82 | 63,873 |
| 21 Jul 2026 | Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | Derivative Exercise and Retained | +4,136 | – | 63,873 |
| 19 Jul 2026 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Sale to Issuer | -3,777 | $14.14 | 66,126 |
| 19 Jul 2026 | James Clemmer | Chief Executive Officer | Sale to Issuer | -45,711 | $14.14 | 604,269 |
| 19 Jul 2026 | Stephen Trowbridge | Chief Financial Officer | Sale to Issuer | -12,067 | $14.14 | 152,665 |
| 19 Jul 2026 | Laura Piccinini | Senior VP and GM of Cardiovascular & International | Sale to Issuer | -8,228 | $14.14 | 58,528 |
| 19 Jul 2026 | Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | Sale to Issuer | -3,838 | $14.14 | 59,737 |
| 15 Jul 2026 | Lawrence Weiss | Chief Legal Officer | Sale to Issuer | -2,267 | $14.14 | 28,632 |
| 14 Jul 2026 | Jan Reed | Independent Director | Other Acquisition | +11,887 | – | 116,921 |
| 14 Jul 2026 | Wesley Johnson | Independent Director | Other Acquisition | +11,887 | – | 155,425 |
| 14 Jul 2026 | Howard Donnelly | Independent Non-Executive Chairperson | Other Acquisition | +11,887 | – | 178,938 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1,916,701 | 4.6% | 1.5 |
| 30 Sep 2026 | 1,294,595 | 3.1% | 2.2 |
| 15 Sep 2026 | 1,343,344 | 3.3% | 3.5 |
| 31 Aug 2026 | 1,363,549 | 3.3% | 5.4 |
| 14 Aug 2026 | 1,353,475 | 3.3% | 2.5 |
| 31 Jul 2026 | 1,221,837 | 3.0% | 2.5 |
No comments yet — be the first to weigh in on ANGO.
Sign in to join the discussion.